(4 months, 1 week ago)
Commons ChamberThe brevity of my answer demonstrates my respect for the observations and experience of my hon. Friend the Member for Stone (Sir William Cash). I completely agree with him, and I will enjoy working with him on this.
I thank the Secretary of State for her very important statement. I welcome every word of it, just as I welcome the final report of the Cass review. I thank Dr Hilary Cass for her outstanding work in lifting the lid on this dangerous ideology and its impact on predominantly young LGB people, and other gender non-conforming young people.
The Secretary of State made an important point about the insinuation of gender ideology and its impact on the health service. As other Members have said, we know that gender ideology has insinuated itself into many of our public bodies and into debate in this place. Pieces of legislation are being proposed in this place that would enforce the very conditions in the Cass report, where gender non-conforming young people are denied proper psychological and psychosocial support to come to a reasonable discussion and end point. What support will the Secretary of State provide to have that conversation and to weed out this ideology elsewhere?
I thank the hon. Gentleman for his advocacy on this issue. I very much hope that all Members will be able to use the evidence produced in this review and report in future debates about legislation so that we can all make informed and correct decisions.
(5 months, 3 weeks ago)
Commons ChamberYes. My hon. Friend raises an incredibly important point. There is no doubt that tobacco and vaping companies are now trying to recruit children, putting vapes, including many illegal vapes, next to the sweet counter with extraordinary flavours such as bubble gum and berry blast, which are clearly not designed, as was originally proposed, for adult smokers to be able to quit smoking by moving to vaping. He is absolutely right and we will bring forward this once-in-a-generation legislation shortly.
We have delivered our manifesto commitment of 50,000 more nurses six months early. There are now almost 361,000 nurses working across the NHS. As part of that, community nursing has grown by over 9% since 2019.
There has been a crisis brewing in community-facing nursing over the past decade, with the number of district nurses down by 40% and health visitor numbers in England and Wales falling by almost a third. What guarantees will the Minister provide that this vital workforce will be supported, when health budgets in all the nations of the UK are under increasing strain and NHS funding faces a £2 billion black hole, and cuts to spending in England have a consequential impact on budgets in Scotland?
Record funding is going into our NHS. In addition to the 9% increase in community nursing since 2019, we are investing over £2.4 billion in education and training through the NHS long term workforce plan, which commits to increasing training places for district nurses by 41% by the end of the decade. Since 2010, we have delivered over 63,300 more nurses and midwives into our NHS.
(1 year, 1 month ago)
Commons ChamberYes, it is true, I am afraid. People are about twice as likely to be waiting for treatment in the Welsh NHS. Waits are also longer in Wales, with 30,000 people waiting more than two years for treatment, even though those have been eliminated in England. England spends more on general practice than Scotland or Wales, despite the fact that Wales has 20% more funding, and England has also grown spending on general practice faster than either Scotland or Wales. We are highly focused on getting good primary care services in England. There are always lessons that we can learn from each other, but there are definitely lessons that Welsh Labour can learn from the English NHS.
The vaccine development and evaluation centre, backed by £65 million for state-of-the-art facilities, at the Porton Down site has been operational since early last year. It supported the autumn vaccine roll-out and the spring vaccine roll-out earlier this year.
In November 2021, Dame Kate Bingham rightly called the decision to withdraw support for the Valneva whole virus vaccine “inexplicable” because a broad portfolio of vaccines is important as we move forward against future variants. The British Society for Immunology states that there is an urgent need for second and third-generation covid vaccines, including universal mucosal vaccines with longer-lasting protective immunity. With growing public concern and mounting clinical and scientific evidence of vaccine injury from mRNA, why is the UK not seeking to harness the power of all technologies instead of establishing an inexplicable exclusive relationship with Moderna?
I confirm to the hon. Gentleman that, in the recent spring campaign, we deployed four approved vaccines—Pfizer-BioNTech, Moderna, Novavax and Sanofi-GSK—as part of our roll-out. We are using a range of vaccines to protect us from the pandemic.
(1 year, 8 months ago)
Commons ChamberI absolutely agree. This was a global pandemic, yet it is the UK Government who are constantly criticised about these contracts and the way in which they were doled out and given. All the motion today asks for is transparency. What have they got to hide?
I thank the right hon. Lady for giving way; she is making a powerful speech. Today has been a really important day, because we have met members of the Fire Brigades Union from across the country who have come down to stand up for a decent salary. That is all we are asking for. What this debate illustrates is that the Government can find billions of pounds to hand over in a crisis to well-connected supporters. If the allegations about the Member from the other place are true, enough money from that alleged dividend would have settled the firefighters’ settlement in Scotland in totality—one person against every firefighter. Will the right hon. Lady confirm that an incoming Labour Government will investigate this matter thoroughly and transparently, and hold anyone who has bent the rules—however they have done so—to justice?
I thank the hon. Member for his point, and he is absolutely right. The Fire Brigades Union members were in Parliament and outside it today. They are frustrated, like many others who have been told that there is not money to give them a pay rise and that, actually, they are going to get a real-terms pay cut. But at the same time, billions of pounds has been wasted. As I said in my opening remarks, £770,000 a day has gone on storing this equipment. It is not acceptable to most people and most members of the public.
I am grateful for this opportunity to come to the House to talk about our vital national efforts on personal protective equipment. Colleagues must cast their minds back to where we were three years ago as we stood on the precipice of a global health emergency, the likes of which had not been seen for over a century. SARS-CoV-2 was not even called covid-19 at that point, and little was known about its impact and transmission. In a matter of a few short weeks, this novel coronavirus pushed global health systems and global PPE supply chains to near breaking point, yet here at home, from a standing start, we initiated work on one of the toughest logistical challenges ever undertaken in peacetime: the provision of PPE for frontline colleagues in health and social care.
At the beginning of the pandemic in one of my first Prime Minister’s questions, I asked the then Prime Minister if he would ensure that profiteering would have no place in this Government’s response to the covid pandemic. Now, when we fast-forward to all these years later, that seems to have been at the very heart of it. The British people were told that this Government were helping them. British industry was told that it was going to be supported. I have persisted in my questions about how the domestic diagnostic industry has been promised work by this Government, yet it is being charged for doing the right thing. Will the Minister apologise—
(2 years, 2 months ago)
Commons ChamberAs I have said before, no country got every decision right during the pandemic, but one thing we did get right was our response in terms of diagnostics, vaccinations and antivirals. That combination allowed us to become the first country in Europe to open up and therefore also to boost our economy. I will make sure that the hon. Gentleman gets the meeting he has asked for.
(2 years, 4 months ago)
Commons ChamberI pay tribute to the hon. Member for Gosport (Dame Caroline Dinenage) for securing this enormously important debate, and to the right hon. Member for Alyn and Deeside (Mark Tami) for his very moving personal account.
My observations are based on a lifetime working in NHS cancer care and on having led the first Teenage Cancer Trust unit at the Middlesex Hospital for a period of time—this was the world in which I existed. I hope that the Minister will pay attention to some of my observations from that career, because I think they will be useful in informing policy.
I agree that there is a need for an overarching strategy, but some of the problems discussed today are perennial; they have been there forever, and there really needs to be a concerted effort to address them. Unfortunately, some of them cannot just be solved with money. In addressing diagnosis, treatment and ultimately outcomes and survivorship, we need to think about why diagnosis is delayed, about why diseases are considered to be rare and about the ultimate impact on outcomes for children and young people. The reason for many late diagnoses is that most GPs never see a case of childhood cancer, let alone cancer in an adolescent, so the effort that goes into raising awareness and training may seem misplaced, given how rare an occurrence it is.
The other challenge is that many of the symptoms with which children present are things that GPs see day in, day out. Fevers, lumps and bumps, lethargy, pains in the tummy—all those symptoms are standard fare, so it is very difficult to cut through to the truth and identify types of cancer. The essential thing is a greater emphasis on driving awareness. It has to be a core part of any differential diagnosis when examining a child that there is always a chance that they have something much more sinister than a cough, cold or fever. It is about making sure that that is built into standard practice.
Another point that I would like to make, although I may run out of time, is that these diseases are incredibly rare. Because the subsets are so rare, it is very difficult to do longitudinal studies.
The hon. Member speaks about the rarity of these diseases. Will he join me in recognising, as other hon. Members have done today, the work on brain cancer that is being done in the name of my predecessor Baroness Tessa Jowell? It provides a model for a children’s cancer mission to bring together expertise in the area.
I thank the hon. Lady for that intervention. I agree: there has been an enormous amount of work across a range of disease profiles, and I want very swiftly to name some of the key people with whom I have had the great pleasure to work in my time. Professor Jeremy Whelan has done a huge amount of work on soft tissue sarcomas and bone tumours, and Professor Andy Pearson from the Royal Marsden Hospital has done a huge amount of work as well. I also want to mention all the members of the multidisciplinary teams who make that kind of research and progress viable.
Let me finally say something about the bigger picture. Cancer does not exist in a bubble; it exists in the social fabric of where we live, and people with cancer, particularly children, are not immune to challenges such as the cost of living crisis. If we want to do a robust piece of work in order to make progress, it must involve research and treatment, but it must also improve the life chances of children more generally.
(2 years, 7 months ago)
Commons ChamberThe fact that the hon. Lady has asked that question demonstrates that this is quite a complex matter. NHS England is looking into it, to work out the best way to roll out the vaccine to that particularly vulnerable group of five to 11-year-olds.
I often pay tribute in this place to the leadership on vaccines of Dame Kate Bingham. Speaking about the cancellation of the Valneva contract in Livingston, Dame Kate described the decision as “short-sighted”, “problematic” and “inexplicable”. She also said that it
“set aside the need to build resilience”
and “capability” through the
“flexible state-of-the-art”
technology that Valneva offered. Moreover, it would help us to tackle vaccine hesitancy and our international responsibilities, owing to the lack of cold chain problems. Will the Government listen to the sage advice of Dame Kate, and reinstate the Valneva contract as a matter of urgency?
I, too, pay tribute to the work of Kate Bingham. Without her leadership, we would be in a worse position in regard to vaccines.
The hon. Gentleman has raised the issue of Valneva in the past, and, as I have said in the past, I cannot comment on commercial decisions.
(2 years, 8 months ago)
Commons ChamberIf my right hon. Friend will allow me, I am about to come to precisely the point he raises.
The second thing about omicron that I want to share is that, although we do not yet have a complete picture of its severity, even if its severity is significantly lower, the much higher transmissibility of omicron means that it still has the potential to overwhelm the NHS. Let us take the current observed doubling time of two years—[Interruption.] Sorry. Let us take the current doubling time of two days. If, for argument’s sake, omicron is only half as severe as delta, after the lag between cases and hospitalisations has taken effect, that would buy us only two days before omicron hospitalisations reach the same level as for delta.
I will do so later.
In England, 10 people are confirmed to have been hospitalised with the omicron variant. I know that some hon. Members have said that, because confirmed hospitalisations from omicron are low, we do not need to act, but it is the fact that omicron hospitalisations are low that means now is the best time to act. We have seen during previous waves—we have already seen this—that the lag between infections and hospitalisations is about two weeks. When infections are rising so quickly, we are likely to see a substantial rise in hospitalisations before any measure starts to have an impact, so there really is no time to lose.
The point about managed quarantine and those people who are already in it is important. I am told that the practice in the past was to require them to complete their quarantine period, but I understand the importance of the point. I have asked for urgent advice about what that means. I hope to add to that very soon.
One of the things we know about omicron is the significant genetic mutations and changes that have happened to the spike protein. This morning, at the Science and Technology Committee, Kate Bingham, the Government’s vaccine tsar, said that the Government’s decision to pull the plug on the Valneva contract was mistaken. Will the Secretary of State make a commitment today to revisit that, given the specific technologies that exist with a whole-virus vaccine, which Ms Bingham described as “having the edge” over other vaccines, and which would help the distribution of vaccines to the rest of the world?
I think the hon. Gentleman will understand that when the Government make decisions on vaccines they take expert advice, most of which comes from the JCVI. We always listen carefully to that advice to make a final decision, but it is coming on a number of occasions and is constantly kept under review.
I wholeheartedly agree with my hon. Friend. Let me be clear: we in the Labour party support this approach because we support British business. This is about giving people the confidence to go out and about despite the presence of omicron.
I thank the shadow Secretary of State for giving way. I wonder whether he shares my concern about reports over the past couple of days that there has been an absence, or a lack, of lateral flow devices to be sent out for testing. What is also alarming is the lack of support for the domestic diagnostics market and the manufacturers in this country of lateral flow devices that are much more accurate and reliable and superior to the current Government lateral flow devices. If these devices are to make a difference, we must have the best quality devices in place.
I agree with the hon. Gentleman. Of course, in order for this measure to work as effectively as we would wish, there has to be an adequate supply of lateral flow tests. I heard what the Secretary of State said yesterday about the availability of testing, but it is no good if the tests are in the warehouse; they need to be available to people where they need them, when they need them. We have had supply issues and those really do need to be resolved, not least in the light of other measures, which I will come to shortly.
(2 years, 9 months ago)
Commons ChamberThe emergence of omicron is not really much of a surprise; it is more a case of when, not if. Anecdotal evidence from South Africa suggests that, while it may be more infectious, the potency seems to be more limited. Of particular concern are the mutations to the spike protein in two specific areas, so what action are the Government taking to put in additional resources to adjuvant therapy development, especially given the impact on monoclonal antibody therapies and the vaccine, and what is the status of genomic surveillance in the UK at present?
First, I think it is fair to say that our genomics surveillance has never been so strong. It was getting stronger even before the pandemic, but because of the pandemic, there has been a huge amount of investment, and it has paid off UK-wide. On the treatments, there is some concern about this new variant and Ronapreve, which is one of the key monoclonal antibodies that we use for treatment, but it is just concern at this point; there is no particular evidence. However, part of the reason for taking these measures is to buy the time we need—two to three weeks—to give our scientists time to assess the risk of this variant properly.
(2 years, 10 months ago)
Commons ChamberUrgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
I hate to tell the Government but there has been a shortage of clinical radiologists for at least 20 years. It takes 12 years to train a clinical radiologist, three to six years to train a radiographer, three to five years to get a specialist nurse and the same for a biomedical scientist. While the investment in the infrastructure is welcome—I would never shy away from welcoming investment in the NHS—there is a very real problem with staffing these centres. What assistance will be provided to NHS trusts to mount an international recruitment drive, because we will have to go to the international market to recruit the staff to these centres?
I am grateful to the hon. Gentleman for welcoming the capital and for his tone. Quite rightly, he highlights the workforce point again. I go back to what I said to the hon. Member for St Albans (Daisy Cooper): on the basis of the figures that I have, since 2010, we have increased the clinical radiology workforce by 48% and the number of diagnostic radiographers is up by 33%. We continue to build on that. The hon. Gentleman is right about the long lead time, which is why it behoves me to say that the increase in numbers is a reflection not just of this Government, but of the previous Government’s investment in this space.